Clinical Characteristics of Seven Patients with Lanthanum Phosphate Deposition in the Stomach
- PMID: 28781325
- PMCID: PMC5596266
- DOI: 10.2169/internalmedicine.8720-16
Clinical Characteristics of Seven Patients with Lanthanum Phosphate Deposition in the Stomach
Abstract
Objective To analyze the clinical characteristics and endoscopic features of patients with lanthanum deposition in the stomach. Patients We retrospectively reviewed seven patients with lanthanum deposition in the stomach who were diagnosed at Okayama Saiseikai General Hospital. We investigated the patient sex, age at diagnosis, medical and medication histories, gastrointestinal symptoms, complications, presence or absence of gastric atrophy, and outcome. We also investigated any changes in the endoscopic features if previous endoscopic images were available. Results Seven patients (six males and one female) had lanthanum deposition. The median age was 65 years (range, 50-79 years). All patients had been undergoing dialysis (continuous ambulatory peritoneal dialysis in one patient, hemodialysis in six patients). The dialysis period ranged from 16 to 73 months (median, 52 months). The patients had all been taking lanthanum carbonate for a period ranging from 5 to 45 months (median, 27 months). Gastric atrophy was noted in 6 patients (85.7%). One patient had difficulty swallowing, and 1 other patient had appetite loss. The other 5 patients were asymptomatic. Endoscopic features included annular whitish mucosa (n = 4), diffuse whitish mucosa (n = 3), and whitish spots (n = 2). Five patients underwent multiple esophagogastroduodenoscopy. The endoscopic features were unchanged in 2 patients, whereas the whitish mucosa became apparent and spread during the course in 3 patients. Conclusion We identified 7 patients with lanthanum deposition in the stomach. All patients showed whitish lesions macroscopically. Although the pathogenicity of gastric lanthanum deposition is uncertain, lanthanum-related lesions in the stomach progressed during continuous lanthanum phosphate intake in several patients.
Keywords: chronic kidney disease; hyperphosphatemia; lanthanum carbonate.
Figures





Similar articles
-
Lanthanum deposition corresponds to white lesions in the stomach.Pathol Res Pract. 2018 Jul;214(7):934-939. doi: 10.1016/j.prp.2018.05.024. Epub 2018 May 23. Pathol Res Pract. 2018. PMID: 29843926
-
Review of the diagnosis of gastrointestinal lanthanum deposition.World J Gastroenterol. 2020 Apr 7;26(13):1439-1449. doi: 10.3748/wjg.v26.i13.1439. World J Gastroenterol. 2020. PMID: 32308345 Free PMC article. Review.
-
One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.Ther Apher Dial. 2010 Feb;14(1):12-9. doi: 10.1111/j.1744-9987.2009.00697.x. Ther Apher Dial. 2010. PMID: 20438515 Clinical Trial.
-
Lanthanum Deposition in the Stomach: Usefulness of Scanning Electron Microscopy for Its Detection.Acta Med Okayama. 2017 Feb;71(1):73-78. doi: 10.18926/AMO/54828. Acta Med Okayama. 2017. PMID: 28238013
-
Early gastric cancer with lanthanum deposition mucosa by endoscopic submucosal dissection: a case report and literature review.Clin J Gastroenterol. 2021 Oct;14(5):1344-1349. doi: 10.1007/s12328-021-01453-z. Epub 2021 Jun 1. Clin J Gastroenterol. 2021. PMID: 34075545 Review.
Cited by
-
Quantitative Visualization of Lanthanum Accumulation in Lanthanum Carbonate-Administered Human Stomach Tissues Using Mass Spectrometry Imaging.Mass Spectrom (Tokyo). 2020;9(1):A0086. doi: 10.5702/massspectrometry.A0086. Epub 2020 Jul 13. Mass Spectrom (Tokyo). 2020. PMID: 32754422 Free PMC article.
-
Gastric lanthanosis (lanthanum deposition) in an immunosuppressed patient that discontinued lanthanum carbonate seven years ago.Clin Case Rep. 2021 Nov 16;9(11):e05075. doi: 10.1002/ccr3.5075. eCollection 2021 Nov. Clin Case Rep. 2021. PMID: 34815874 Free PMC article.
-
Frequent Involvement of the Duodenum with Lanthanum Deposition: A Retrospective Observational Study.Intern Med. 2019 Aug 15;58(16):2283-2289. doi: 10.2169/internalmedicine.2398-18. Epub 2019 May 22. Intern Med. 2019. PMID: 31118380 Free PMC article.
-
Lanthanum phosphate binder-induced iron deficiency anaemia.BMJ Case Rep. 2019 Mar 15;12(3):e226157. doi: 10.1136/bcr-2018-226157. BMJ Case Rep. 2019. PMID: 30878952 Free PMC article.
-
Lanthanum deposition in the gastric mucosa in a patient treated with haemodialysis.BMJ Case Rep. 2019 May 8;12(5):e230550. doi: 10.1136/bcr-2019-230550. BMJ Case Rep. 2019. PMID: 31068359 Free PMC article. No abstract available.
References
-
- Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19: 303-317, 1992. - PubMed
-
- Shigematsu T; Lanthanum Carbonate Research Group.. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. Ther Apher Dial 14: 12-19, 2010. - PubMed
-
- Tsuchida K, Nagai K, Yokota N, Minakuchi J, Kawashima S. Impact of lanthanum carbonate on prognosis of chronic hemodialysis patients: a retrospective cohort study (Kawashima Study). Ther Apher Dial 20: 142-148, 2016. - PubMed
-
- Giotta N, Marino AM. Pharmacoeconomic analysis: analysis of cost-effectiveness of lanthanum-carbonate (Lc) in uncontrolled hyperphosphatemia in dialysis. Value Health 18: A511, 2015.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical